These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 1651682)

  • 1. [Combination cancer chemotherapy using a DNA topoisomerase inhibitor CPT-11, as a core agent--the in vitro evaluation].
    Oguro M; Seki Y
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1556-61. PubMed ID: 1651682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
    Saijo N; Nishio K; Kubota N; Kanzawa F; Shinkai T; Karato A; Sasaki Y; Eguchi K; Tamura T; Ohe Y
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S112-7. PubMed ID: 8070019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Camptothecin analogues with enhanced antitumor activity at acidic pH.
    Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
    Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The water-insoluble camptothecin analogues: promising drugs for the effective treatment of haematological malignancies.
    Pantazis P
    Leuk Res; 1995 Nov; 19(11):775-88. PubMed ID: 8551794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.
    Kanzawa F; Koizumi F; Koh Y; Nakamura T; Tatsumi Y; Fukumoto H; Saijo N; Yoshioka T; Nishio K
    Clin Cancer Res; 2001 Jan; 7(1):202-9. PubMed ID: 11205910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effect of combined administration with CPT-11 and 5-fluorouracil in vitro and in vivo.
    Satoh H; Ohtomo M; Ishikawa H; Kamma H; Ohtsuka M; Hasegawa S
    Cancer Biochem Biophys; 1999 Jul; 17(1-2):59-67. PubMed ID: 10738902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mechanisms of acquired resistance to DNA topoisomerase I inhibitors].
    Okada K; Andoh T
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1562-7. PubMed ID: 1651683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of CPT-11 and its active metabolite SN-38.
    Lavelle F; Bissery MC; André S; Roquet F; Riou JF
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):11-20. PubMed ID: 8633248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [DNA topoisomerase inhibitor as chemotherapeutic drug--clinical point of view].
    Taguchi T
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1574-8. PubMed ID: 1651685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
    Chen TC; Su S; Fry D; Liebes L
    Cancer; 2003 May; 97(9 Suppl):2363-73. PubMed ID: 12712458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase I inhibitors. An overview of the camptothecin analogs.
    Burris HA; Fields SM
    Hematol Oncol Clin North Am; 1994 Apr; 8(2):333-55. PubMed ID: 8040144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance.
    Kanzawa F; Sugimoto Y; Minato K; Kasahara K; Bungo M; Nakagawa K; Fujiwara Y; Liu LF; Saijo N
    Cancer Res; 1990 Sep; 50(18):5919-24. PubMed ID: 2168285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.
    Sugimoto Y; Tsukahara S; Oh-hara T; Isoe T; Tsuruo T
    Cancer Res; 1990 Nov; 50(21):6925-30. PubMed ID: 2170010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
    Fukuda M; Nishio K; Kanzawa F; Ogasawara H; Ishida T; Arioka H; Bojanowski K; Oka M; Saijo N
    Cancer Res; 1996 Feb; 56(4):789-93. PubMed ID: 8631015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment.
    Ozawa Y; Kusano K; Owa T; Yokoi A; Asada M; Yoshimatsu K
    Cancer Chemother Pharmacol; 2012 May; 69(5):1353-62. PubMed ID: 22349812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical and clinical trials of topoisomerase inhibitors.
    Saijo N
    Ann N Y Acad Sci; 2000; 922():92-9. PubMed ID: 11193928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
    Hentze H; Latta M; Künstle G; Dhakshinamoorthy S; Ng PY; Porter AG; Wendel A
    Hepatology; 2004 May; 39(5):1311-20. PubMed ID: 15122760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interaction of buthionine sulphoximide (BSO) and the topoisomerase I inhibitor CPT-11.
    Sawyer TE; Bonner JA
    Br J Cancer Suppl; 1996 Jul; 27():S109-13. PubMed ID: 8763860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
    Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
    J Surg Oncol; 1993 Jun; 53(2):97-103. PubMed ID: 8388965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.